Products for Research Use Only

Ditiocarb sodium

CAT: 0804-HY-B1637-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1637-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases[1][2][3][4].
CAS Number
148-18-5
Product Name Alternative
Sodium diethyldithiocarbamate
UNSPSC
12352211
Hazard Statement
H315, H319, H335
Target
Biochemical Assay Reagents; HIV
Type
Reference compound
Related Pathways
Anti-infection; Others
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Sodium_diethyldithiocarbamate.html
Purity
98.29
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
S=C(S[Na])N(CC)CC
Molecular Formula
C5H10NNaS2
Molecular Weight
171.26
Precautions
H315, H319, H335
References & Citations
[1]Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41 (4) :289-293.|[2]Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265 (12) :1538-44.|[3]Perchellet JP, et al. Inhibition of multistage tumor promotion in mouse skin by diethyldithiocarbamate. Cancer Res. 1987 Dec 1;47 (23) :6302-9.|[4]Borch RF, et al. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci U S A. 1979 Dec;76 (12) :6611-4.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported